For the complete program registry, see ClinicalTrials.gov
5 Figure 3: Pharmacy claims data show that 63% of patients initiating Wegovy or Zepbound in early 2024 remained on therapy at one year, up from 40% in the 2023 cohort
Heres what I tell my clients think about these four things: Are you in perimenopause, post-menopause, or another midlife transition
Also, the efficacy and safety of tirzepatide may have a wider perspective for its use beyond patients with T2DM or obesity [9, 10]
Current Research and Clinical Trials Early Findings and Promising Results The exploration into GLP-1 receptor agonists (GLP-1 RAs) for depression is still in its early stages, but the initial findings are quite encouraging
Marquez-Meneses JD, Olaya-Bonilla SA, Barrera-Carreo S, Tibaduiza-Arvalo LC, Forero-Crdenas S, Carrillo-Vaca L, Rojas-Rodrguez LC, Calderon-Ospina CA, Rodrguez-Quintana J (2025) GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives
